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Abstract
Small therapeutic peptides represent a promising field for the treatment of pathologies such
as cardiac diseases. However, the lack of proper target-selective carriers hampers their
translation towards a potential clinical application. Aptamers are cell-specific carriers that
bind with high affinity to their specific target. However, some limitations on their conjugation
to small peptides and the functionality of the resulting aptamer-peptide chimera exist. Here,
we generated a novel aptamer-peptide chimera through conjugation of the PDGFRβ-target-
ing Gint4.T aptamer to MP, a small mimetic peptide that via targeting of the Cavβ2 subunit of
the L-type calcium channel (LTCC) can recover myocardial function in pathological heart con-
ditions associated with defective LTCC function. The conjugation reaction was performed by
click chemistry in the presence of N,N,N’,N’,N”-pentamethyldiethylenetriamine as a Cu (I)
stabilizing agent in a DMSO-free aqueous buffer. When administered to cardiac cells, the
Gint4.T-MP aptamer-peptide chimera was successfully internalized in cells, allowing the
functional targeting of MP to LTCC. This approach represents the first example of the use of
an internalizing aptamer for selective delivery of a small therapeutic peptide to cardiac cells.
Introduction
Therapeutic peptides for clinical applications have recently obtained increasing interest, reach-
ing over 60 FDA-approved products on the market and more than 150 mimetic peptides in
clinical trials [1, 2]. This achievement has been facilitated by a range of novel peptide technolo-
gies, allowing for dedicated chemical design strategies to avoid aggregation, increase solubility,
and extend the stability of peptides [3, 4]. On the other hand, cell membrane permeability and
low cell-specific targeting are still challenging issues and despite some encouraging results
obtained with a combined use of cell penetrating peptides, such as TAT and R7W [5], these
issues weaken the safe and efficient clinical application of current therapeutic peptides.
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Recently, we developed a cell-penetrating therapeutic peptide (R7W-MP), which is
endowed with the ability to recover myocardial contractility in pathological heart conditions
via restoration of L-type calcium channel (LTCC) density at the plasma membrane [6, 7].
LTCC is a multi-protein complex composed of a pore-forming Cavα1.2 unit and accessory
subunits, such as the cytoplasmic Cavβ2, which is the chaperone of the pore unit. In the heart,
LTCC plays a critical role in regulating cardiac contractility [8]. In line with this, acquired and
genetically determined LTCC dysfunctions have been causally associated with various condi-
tions of human cardiovascular pathologies [9–12]. R7W-MP is composed of a R7W cell-pene-
trating peptide fused to an 11 acid peptide (MP), which is the active component of the
therapeutic molecule. MP, which mimics an amino acidic stretch of the C-terminal tail of the
Cavβ2 cytosolic chaperone, is designed to specifically target the Tail Interacting Domain (TID)
within the Cavβ2 globular domain, facilitating the restoration of Cavα1.2 protein density at the
plasma membrane in heart conditions associated with altered LTCC levels and function [6].
Mechanistically, R7W-MP restores at the plasma membrane the reduced protein levels of dys-
regulated Cavα1.2 by acting on both reverse (degradation) and forward (maturation) traffick-
ing of the channel protein, thereby recovering LTCC density. However, despite the
encouraging results obtained for the therapeutic treatment of LTCC-related cardiac condi-
tions, such as diabetic cardiomyopathy [6, 7], the use of R7W-MP faces limitations due to the
broad tissue targeting of the R7W moiety, which is not cell specific and may thereby lead to
potential side effects at other locations where the Cavβ2 target is expressed. This limitation
highlights the critical need for the identification of novel and more cell-specific targeting
carriers.
Aptamers, which are short single stranded oligonucleotides of DNA, RNA, or modified
RNA and DNA, are emerging as a very interesting class of molecules that can fold into com-
plex tertiary structures and bind with high affinity to a specific target [13]. In particular, iso-
lated from combinatorial libraries by a Systematic Evolution of Ligands by Exponential
enrichment (SELEX) process [14, 15], aptamers can be designed for the recognition of any sur-
face receptor undergoing receptor-mediated cell internalization, thereby serving as cell-selec-
tive carriers for a secondary reagent. Thus, by conjugation to specific aptamers, off-target
effects of therapeutic peptides might be greatly reduced [16]. Moreover, compared to other tar-
geting ligands and monoclonal antibodies, aptamers show many additional advantages, such
as low toxicity, high specificity, and superior stability in biological fluids.
Here, we addressed the specific delivery of MP to cardiac cells and developed a novel
approach based on direct conjugation of the therapeutic peptide to a cell internalizing aptamer
as carrier. In particular, we designed a novel aptamer-peptide chimera and conjugated the
therapeutic MP directly to Gint4.T, an aptamer specifically binding to the platelet-derived
growth factor receptor-β, PDGFRβ [17], which is a receptor expressed in cardiomyocytes [18].
Results obtained with the cell-targeting Gint4.T-MP chimera provide the proof-of-concept for
a significant step forward towards a safe and selective use of MP for the treatment of cardiac
disorders associated with LTCC abnormalities [9, 10, 19]. Furthermore, the development of
aptamer-peptide conjugates has a broader applicability for the selective delivery and intracellu-
lar penetration of therapeutic peptides in several diseases, including cancer [13].
Material and methods
Peptide synthesis
Peptides were obtained by solid phase synthesis using standard protocols [20]. Peptides were
purified by HPLC on a Phenomenex Axia Jupiter 4 μm Proteo 90 Å (250x21.2) column using a
gradient of acetonitrile (0.1% TFA) in water (0.1% TFA) from 5 to 50% in 20 minutes and
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characterized by LC-MS on a LC-MS Agilent Technologies 6230 ESI-TOF using a Phenom-
enex Jupiter 3 μm C18 (150x2.0 mm) column.
MP sequence: NorLeu-DQRPDREAPRS. Calculated mass (Da): 1479.3510; found:
740.8723 [M+2H]2+, 494.2513 [M+3H]3+.
Scramble sequence: NorLeu-DQPPSRRDERA. Calculated mass (Da): 1479.3510; found:
740.8723 [M+2H]2+, 494.2513 [M+3H]3+.
Protocol for the conjugation of peptides to the aptamer Gint4.T
5 nmol of Gint4.T aptamer, equipped with a 3’-propargyl adenosine at the 3’ end in place of
standard adenosine (MW: 10700 Da) were reacted with 7.5 nmol of MP (or scramble, scr) in
100 mM Tris HCl, pH 7.5 buffer containing CuSO4 • 5H2O (5 μmol), ascorbic acid (0.1 μmol),
and pentamethyldiethylenetriamine (PMDETA) (0.01% v/v) in a total reaction volume of
500 μL. The reaction proceeded at room temperature under argon for 2 hours. The crude was
stored at -20˚C. The sample was purified by PAGE purification on a 12% acrylamide 7 M urea
gel, using Gint4.T as control.
RT-PCR of the purified sample was carried out to demonstrate the presence of the aptamer
in the conjugate. 500 ng of Gint4.T and Gint4.T-MP were retro-transcribed with Reverse
Transcriptase M-MuLV (Roche Life Science) and amplified with FIREPol DNA Polymerase
(Microtech) using specific primers: Gint4.T FW: 5’ TAATACGACTCACTATAGGGTGTCGTG
GGGCA; Gint4.T RV: 5’ TGTCGAATTGCATTTACT.
Alkaline hydrolysis of the pure sample was also performed to demonstrate the presence of
the peptide moiety in the conjugate. Briefly, the conjugate (4.4 μg in 18 μL H2O) was diluted
with 12 μL Na2CO3 (4 mM), NaHCO3 (46 mM) buffer, pH 9.2 and incubated at 95˚C for 90
minutes. At the end of the reaction the crude was analyzed by LC-MS as described earlier.
Cell culture conditions and treatment
Cardiac muscle cells (HL-1) were cultured in Claycomb medium (Sigma) supplemented with
10% FBS (Sigma), 100 U/ml penicillin, 0.1 mg/ml streptomycin (Euroclone), 1% Ultragluta-
mine 1 (Lonza), and 0.1M Norepirephrine (Sigma) in a gelatin/fibronectin pre-coated flask.
The treatment with peptides (R7W-MP or R7W-scr) or aptamers (Gint4.T, Gint4.T, or Gint4.
T-scr) was performed in serum-free medium (Opti-MEM I reduced-serum medium, Thermo
Fisher Scientific). After 24 h, cells were collected and analyzed.
Calcium assay
The Fluo-4 Direct Calcium Assay was performed as described by the manufacturer (Thermo
Fisher Scientific). Briefly, HL-1 cells, pretreated as described, were stimulated with Fluo-4
Direct calcium reagent (Thermo Fisher Scientific) and signals were detected one hour post
treatment. 10 mM Bay K8644 (Sigma) was added to cells and signals were immediately
detected using a Synergy 4 instrument (BioTek). Results were analyzed using Prism 6.0 soft-
ware (GraphPad Software, CA).
Western blot analyses
Protein expression was evaluated by Western blot analyses. Samples were homogenized in
RIPA buffer (150 mM NaCl, 10 mM Tris, pH 7.2, 0.1% SDS, 1% Triton-X100, 5 mM EDTA,
100 μM Na3VO4, 10 mM NaF), and Protease inhibitor 1X (Thermo Fisher Scientific), loaded
onto a 4–10% acrylamide gradient gel, separated by electrophoresis, and transferred to a nitro-
cellulose membrane (Millipore). Primary antibodies against the following proteins were used:
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Cavα1.2 (Abcam), GAPDH (14C10) (Cell Signaling Technology). Goat anti-mouse-HRP and
Goat anti-rabbit-HRP (Thermo Fisher Scientific) were used as secondary antibodies. ECL
(Millipore) was used for protein detection using a Chemidoc MP Imaging System (Biorad).
Image J software (National Institutes of Health) was used for densitometry analysis.
Statistical analysis
Prism 6.0 software (GraphPad Software, CA) was used to assess normality of the data using the
Kolmogorov-Smirnov (K-S) test and for statistical comparisons using Dunn’s test.
Results and discussion
Aptamer-peptide conjugation
To provide guidance for targeting of MP to the heart, we conjugated it to the Gint4.T aptamer,
which we previously showed promotes the functional internalization of miRNAs and anti-
miRs in a PDGFRβ-dependent manner [21, 22]. This was achieved through Cu (I)-mediated
click chemistry, an approach poorly explored mainly due to difficulties associated with RNA
degradation caused by Cu (I) disproportionation and subsequent redox reactions. Ligands,
such as tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) [23] or the water-soluble
tris(3-hydroxypropyl-triazolylmethyl)amine (THPTA) [24], have been employed to stabilize
Cu (I) and prevent the metal disproportionation reaction. In addition, the combination of
TBTA with DMSO has recently been employed for the successful conjugation of RNA to pep-
tides [25]. Nonetheless, this possibility still faces critical issues as DMSO may affect RNA sec-
ondary structure [26] and thereby disturb the aptamer-mediated cell internalization. Thus, we
here decided to perform all reactions in DMSO-free aqueous buffers using N,N,N’,N’,N”-pen-
tamethyldiethylenetriamine (PMDETA) as a Cu (I) stabilizing agent for the conjugation of the
RNA aptamer Gint4.T to MP. The advantage of PMDETA is its water solubility and ease to
separate from the reaction mixture upon purification of the conjugate [27]. The sequence of
the aptamer employed for the conjugation is identical to that previously reported by our group
[17] with the exception of the 3’-propargyl adenosine, which was used for the conjugation in
place of standard adenosine at the 3’ end. The introduction of 2’-fluoro modified pyrimidine
bases grants an increased stability of the RNA aptamer. The reaction is performed between the
aptamer and the MP peptide, which is modified at its N-terminus by an azido-norleucine resi-
due (Fig 1A). The extent of the reaction, which smoothly proceeded in the buffer using a slight
excess of the peptide in 2 hours, was monitored by migration analysis of the resulting high
molecular weight product through urea-acrylamide electrophoresis (Fig 1B). Purification of
the Gint4.T-MP conjugate was then achieved by PAGE and the final product assessed by
RT-PCR analysis to confirm that the Gint4.T sequence is indeed present in the purified high
molecular weight Gint4.T-MP (Fig 1C). To further characterize the conjugate and confirm the
presence of the peptide in the isolated compound, purified Gint4.T-MP was subjected to alka-
line degradation (to remove the RNA) followed by LC-MS analysis. Results showed a product
with a molecular weight of 2135 Da consistent with the degradation of the aptamer up to the
last two bases at the 3’ end (i.e. the clicked propargyl adenosine and the 2’-fluoro-cytosine,
data not shown).
Gint4.T-MP targets cardiac cells and restores LTCC protein levels
To determine whether the Gint4.T-MP chimera facilitates cell internalization of the MP, thus
allowing its therapeutic effects on restoring Cavα1.2 protein stability, we next explored its
recovery effect in a cardiac context where all LTCC players are physiologically expressed. In
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line with this, HL-1 cardiac cells were subjected to serum starvation, which corresponds to a
LTCC destabilizing condition [6], whereafter Cavα1.2 protein levels were evaluated with or
without treatment with either Gint4.T-MP or R7W-MP conjugates. As previously shown by
our group [6], treatment of cardiac cells with R7W-MP, where the MP is fused to R7W cell
penetrating peptide, allowed for a full restoration of Cavα1.2 amounts, whereas no such effect
was obtained with R7W fused to a scramble peptide (R7W-scr) (Fig 2). Notably, administra-
tion of Gint4.T-MP lead to similar effects and successfully recovered the protein levels of
Cavα1.2 to levels comparable to those obtained by R7W-MP administration or in serum-rich
Fig 1. Gint4.T-MP conjugation. (A) Strategy for the conjugation of Gint4.T aptamer and MP peptide. (B) Analysis of
click chemistry reactions between Gint4.T 3’-propargyl adenosine and MP by 12% acrylamide 7 M urea
electrophoresis in two different reaction conditions: 1:1,25 (aptamer:peptide) ratio and 1:3 (aptamer:peptide) ratio.
The star indicates the Gint4.T/peptide conjugates. (C) Characterization of the aptamer portion by RT-PCR. Gint4.T
and Gint4.T-MP were reverse-transcribed, amplified, and loaded on a 3% agarose gel. The star indicates Gint4-T,
which is 53 nt. Neg. Ctl RT and Neg. Ctl PCR refers to the mix of reverse-transcription and PCR without template.
https://doi.org/10.1371/journal.pone.0193392.g001
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cells (Fig 2). On the other hand, no effect was obtained when the Gint4.T chimera conjugated
to a scramble peptide (Gint4.T-scr) was applied.
Gint4.T-MP recovers LTCC-dependent calcium fluxes in cardiac cells
To functionally evaluate the Gint4.T-MP effect on channel density, we next performed a fluo-
rescence-based assay of LTCC-dependent intracellular calcium fluxes in live cells. HL-1 cells
were treated with the LTCC-specific agonist (BAYK8644), which through opening of the chan-
nel leads to an increase in intracellular calcium, which was measured in a fluorometric cell-
based assay. As expected, a dramatic drop in intracellular calcium accumulation was observed
in serum-starved HL-1 cardiac cells compared to the control state (Fig 3 and S1 Table). On the
Fig 2. Gint4.T-MP conjugate reestablishes LTCC protein levels in HL-1 cardiac cells. Western Blot analysis for
Cavα1.2 in total protein lysates from HL-1 cells treated as indicated.
https://doi.org/10.1371/journal.pone.0193392.g002
Fig 3. Gint4.T-MP conjugate reestablishes intracellular calcium levels in HL-1 cardiac cells. Intracellular calcium
analysis in HL-1 cells treated as indicated. (n = 6, Dunnett’s multicomparison test). Individual data points are available
upon request.
https://doi.org/10.1371/journal.pone.0193392.g003
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other hand, treatment with increasing doses of Gint4.T-MP resulted in an incremental recov-
ery of LTCC-dependent intracellular calcium accumulation. This effect was not obtained
when the same doses of either Gint4.T-scr or unconjugated Gint4.T were applied. The results
achieved with Gint4.T-MP, which are causally linked to the effective intracellular targeting of
MP to its cytosolic target Cavβ2, were similar to those obtained with the administration of the
R7W-MP. Altogether, these data support the concept that the therapeutic MP, when conju-
gated to the cell internalizing Gint4.T aptamer, can be efficiently directed to PDGFRβ-express-
ing cells and internalized for functional targeting of LTCC.
Possessing key advantages over large proteins or antibodies, including easy synthesis and
low toxicity, peptides are emerging as highly effective therapeutics for the treatment of impor-
tant fatal diseases, such as neoplastic and cardiovascular diseases [1, 2]. However, although
cell-penetrating therapeutic peptide chimeras with high therapeutic target specificity have
been developed, including the R7W-MP peptide [6], the lack of selective targeting to the dis-
eased organ and tissue is a severe obstacle for their effective translation to the clinic. Our dem-
onstration that conjugation of R7W-free MP to an internalizing aptamer can mediate its
uptake in cardiac cells and functional targeting of cytosolic Cavβ2, may open up for therapeutic
applications that are more selective to the heart. Using Gint4.T, we provide the proof-of-con-
cept that the approach is effective and might be exploited within the context of the growing
number of therapeutic peptides. However, due to the binding of Gint4.T to the PDGFRβ cell-
surface receptor, which in addition to cardiomyocytes is expressed also in other cell types,
such as smooth muscle cells and fibroblasts [28–30], further studies are required to identify
internalizing aptamers with higher selectivity for the heart.
Furthermore, our proposed conjugation is achieved under favorable conditions, which
include i) the absence of co-solvents potentially affecting the structure of the aptamer, and ii)
the use of a water-soluble and cost-effective Cu (I) stabilizing agent, such as PMDETA.
Conclusions
In conclusion, we here report a strategy that provides more selective delivery of MP therapeu-
tic peptide to cardiomyocytes. To the best of our knowledge, this represents the first example
of the use of an internalizing aptamer for delivery of a small therapeutic peptide to cardiac
cells.
Supporting information
S1 Table. Data from intracellular calcium analysis in HL-1 treated cells.
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